Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension

Current Hypertension Reviews

Volumn 9, Issue 2, 2013, Pages 108-114

  Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Benidipine; Chronic kidney disease; Hypertension; L T type CCBs; Renoprotective effects

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; ALDOSTERONE; AMLODIPINE; BENIDIPINE; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; EFONIDIPINE; MANIDIPINE; MEPIRODIPINE; NIFEDIPINE; NILVADIPINE; REACTIVE OXYGEN METABOLITE;

ADRENAL GLAND; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIOLE; ARTICLE; CELL MEMBRANE; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; DISEASE COURSE; DRUG BINDING SITE; DRUG EFFICACY; DRUG RECEPTOR BINDING; HORMONE INHIBITION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENAL ARTERY; RENAL PROTECTION; SENSORY NERVE;

CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; DIHYDROPYRIDINES; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES;

EID: 84881494531     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/15734021113099990005     Document Type: Article

References (47)

1. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-53.
2. Fujita T, Ando K, Nishimura H, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-9.
3. Takenaka T, Takane H, Okada H, Ohno Y, Suzuki H. Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases. NDT Plus 2009; 2: 192-3.
4. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009; 32: 270-5.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney inter Suppl 2012; 2: 337-414.
6. Yao K, Nagashima K, Miki H. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, longacting calcium channel blocker. J Pharmacol Sci 2006; 100: 243-61.
7. Saito I, Suzuki H, Kageyama S, Saruta T. Effect of antihypertensive treatment on cardiovascular events in elderly hypertensive patients: Japan's Benidipine Research on Antihypertensive Effects in the Elderly (J-BRAVE). Clin Exp Hypertens 2011; 33: 133-40.
8. Furukawa T, Nukada T, Miura R, et al. Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005; 45: 241-6.
9. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T. Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999; 291: 464-73.
10. Omae K, Ogawa T, Nitta K. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. Heart Vessels 2009; 24: 301-7.
11. Yamada H, Suga N, Maeda K, et al. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study. Arzneimittelforschung 2010; 60: 64-70.
12. Inoue S, Tomino Y. Effects of calcium antagonists in hypertensive patients with renal dysfunction: a prospective, randomized, parallel trial comparing benidipine and nifedipine. Nephrology 2004; 9: 265-71.
13. Hayashi K, Homma K, Wakino S, et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010; 59: 84-95.
14. Hayashi K, Wakino S, Homma K, Sugano N, Saruta T. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci 2005; 99: 221-7.
15. Shirakura S, Sano J, Karasawa A, Kubo K. Protective effect of benidipine against the development of glomerular sclerosis in experimental nephrotic syndrome. Jpn J Pharmacol 1992; 59: 461-7.
16. Tang Z, Fukui M, Wang LN, Mizokuchi M, Shirato I, Tomino Y. Effect of benidipine on decreasing glomerular expansion in the experimental nephrotic syndrome. Nephron 1995; 70: 369.
17. Struthers AD, MacDonald TM. Review of aldosterone-and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-70.
18. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-81.
19. Yoshida K, Kim-Mitsuyama S, Wake R, et al. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005; 28: 447-55.
20. Akizuki O, Inayoshi A, Kitayama T, et al. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584: 424-34.
21. Yamamoto E, Kataoka K, Dong YF, et al. Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats. J Hypertens 2010; 28: 1321-9.
22. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J 2011; 32: 2739-47.
23. Shou I, Wang LN, Takahashi Y, Fukui M, Tomino Y. Effects of benidipine hydrochloride on antioxidant enzyme activity in strokeprone spontaneous hypertensive rats (SHR-SP). J Clin Lab Anal 1997; 11: 158-62.
24. Uzu T, Nishimura M, Fujii T, et al. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome. Hypertens Res 2007; 30: 161-5.
25. Morikawa T, Okumura M, Konishi Y, Okada N, Imanishi M. Effects of benidipine on glomerular hemodynamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res 2002; 25: 571-6.
26. Kawata T, Hashimoto S, Koike T. Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1997; 30: 431-6.
27. Yue W, Kimura S, Fujisawa Y, et al. Benidipine dilates both preand post-glomerular arteriole in the canine kidney. Hypertens Res 2001; 24: 429-36.
28. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-74.
29. Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69: 1264-71.
30. Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303-9.
31. Ando K. COmbination Strategy on renal function of the benidipine or diuretics treatMent with RAS inhibitOrs in CKD hypertensive population. UMIN-CTR Clinical Trial UMIN000002143. 2009 July. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr. cgi?function=brows&action=brows&type=summary&recptno=R00 0002564&language=E.
32. Ando K, Ueshima K, Tanaka S, et al. Comparison of the antialbuminuric effects between L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: The study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. J Hypertens. 2012 Sep; 30: e-Supplement 1, e-159. Available from: http://www. ish2012.org/docs/01%20ISH%202012%20Journal%20of%20Hype rtension.pdf
33. Abe M, Okada K, Maruyama N, et al. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. Expert Opin Investig Drugs 2010; 19: 1027-37.
34. Tomino Y, Shimizu Y, Hamada C, et al. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease. J Nephrol 2011; 24: 756-63.
35. Suzuki H, Saruta T; Calcium Antagonist in Progressive Renal Insufficienct Study Group. Effects of calcium antagonist, benidipine, on the progression of chronic renal failure in the elderly: a 1-year follow-up. Clin Exp Hypertens 2001; 23: 189-201.
36. Abe M, Okada K, Maruyama N, et al. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34: 268-73.
37. Fuji Y, Suzuki H, Katsumata H, Nakajima S, Saruta T. Hormonal and renal responses to oral once-daily calcium entry blocker in normotensive and hypertensive persons. J Cardiovasc Pharmacol 1988; 11: 438-43.
38. Nakamura T, Sato E, Fujiwara N, et al. Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in earlystage chronic kidney disease. Am J Med Sci 2010; 339: 157-63.
39. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
40. de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459-64.
41. Bakris GL, Sarafidis PA, Weir MR, et al. ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-81.
42. Hayashi K, Saruta T, Goto Y, Ishii M; JATOS Study Group. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res 2010; 33: 1211-20.
43. Rakugi H, Ogihara T, Matsuzaki M, Umemoto S, Ohashi Y, Saruta T. Combination therapy in hypertension with CKD-A subanalysis of combination therapy of hypertension to prevent cardiovascular events (COPE) Trial. J Hypertens 2012 Sep; 30: e-Supplement 1, e-
44. Available from: http://www.ish2012.org/docs/01%20ISH% 202012%20Journal%20of%20Hypertension.pdf
45. Ishimitsu T, Kameda T, Akashiba A, et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621-6.
46. Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333: s321-6.
47. Ogawa S, Mori T, Nako K, Ito S. Combination therapy with reninangiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res 2008; 31: 1147-55.